Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 2
1994 1
1995 2
1996 4
1997 6
1998 2
1999 1
2000 3
2001 7
2002 6
2003 7
2004 8
2005 7
2006 5
2007 8
2008 7
2009 9
2010 10
2011 11
2012 13
2013 14
2014 12
2015 19
2016 19
2017 25
2018 28
2019 27
2020 28
2021 30
2022 28
2023 27
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

352 results

Results by year

Filters applied: . Clear all
Page 1
Cancer vaccines: the next immunotherapy frontier.
Lin MJ, Svensson-Arvelund J, Lubitz GS, Marabelle A, Melero I, Brown BD, Brody JD. Lin MJ, et al. Among authors: melero i. Nat Cancer. 2022 Aug;3(8):911-926. doi: 10.1038/s43018-022-00418-6. Epub 2022 Aug 23. Nat Cancer. 2022. PMID: 35999309 Review.
Dendritic cells in cancer immunology and immunotherapy.
Wculek SK, Cueto FJ, Mujal AM, Melero I, Krummel MF, Sancho D. Wculek SK, et al. Among authors: melero i. Nat Rev Immunol. 2020 Jan;20(1):7-24. doi: 10.1038/s41577-019-0210-z. Epub 2019 Aug 29. Nat Rev Immunol. 2020. PMID: 31467405 Review.
Advances in immunotherapy for hepatocellular carcinoma.
Sangro B, Sarobe P, Hervás-Stubbs S, Melero I. Sangro B, et al. Among authors: melero i. Nat Rev Gastroenterol Hepatol. 2021 Aug;18(8):525-543. doi: 10.1038/s41575-021-00438-0. Epub 2021 Apr 13. Nat Rev Gastroenterol Hepatol. 2021. PMID: 33850328 Free PMC article. Review.
Paradigms on Immunotherapy Combinations with Chemotherapy.
Salas-Benito D, Pérez-Gracia JL, Ponz-Sarvisé M, Rodriguez-Ruiz ME, Martínez-Forero I, Castañón E, López-Picazo JM, Sanmamed MF, Melero I. Salas-Benito D, et al. Among authors: melero i. Cancer Discov. 2021 Jun;11(6):1353-1367. doi: 10.1158/2159-8290.CD-20-1312. Epub 2021 Mar 12. Cancer Discov. 2021. PMID: 33712487 Review.
Immunological Mechanisms Responsible for Radiation-Induced Abscopal Effect.
Rodríguez-Ruiz ME, Vanpouille-Box C, Melero I, Formenti SC, Demaria S. Rodríguez-Ruiz ME, et al. Among authors: melero i. Trends Immunol. 2018 Aug;39(8):644-655. doi: 10.1016/j.it.2018.06.001. Epub 2018 Jul 11. Trends Immunol. 2018. PMID: 30001871 Free PMC article. Review.
Cytokines in clinical cancer immunotherapy.
Berraondo P, Sanmamed MF, Ochoa MC, Etxeberria I, Aznar MA, Pérez-Gracia JL, Rodríguez-Ruiz ME, Ponz-Sarvise M, Castañón E, Melero I. Berraondo P, et al. Among authors: melero i. Br J Cancer. 2019 Jan;120(1):6-15. doi: 10.1038/s41416-018-0328-y. Epub 2018 Nov 9. Br J Cancer. 2019. PMID: 30413827 Free PMC article. Review.
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.
Yau T, Park JW, Finn RS, Cheng AL, Mathurin P, Edeline J, Kudo M, Harding JJ, Merle P, Rosmorduc O, Wyrwicz L, Schott E, Choo SP, Kelley RK, Sieghart W, Assenat E, Zaucha R, Furuse J, Abou-Alfa GK, El-Khoueiry AB, Melero I, Begic D, Chen G, Neely J, Wisniewski T, Tschaika M, Sangro B. Yau T, et al. Among authors: melero i. Lancet Oncol. 2022 Jan;23(1):77-90. doi: 10.1016/S1470-2045(21)00604-5. Epub 2021 Dec 13. Lancet Oncol. 2022. PMID: 34914889 Clinical Trial.
Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3.
Wang J, Sanmamed MF, Datar I, Su TT, Ji L, Sun J, Chen L, Chen Y, Zhu G, Yin W, Zheng L, Zhou T, Badri T, Yao S, Zhu S, Boto A, Sznol M, Melero I, Vignali DAA, Schalper K, Chen L. Wang J, et al. Among authors: melero i. Cell. 2019 Jan 10;176(1-2):334-347.e12. doi: 10.1016/j.cell.2018.11.010. Epub 2018 Dec 20. Cell. 2019. PMID: 30580966 Free PMC article.
Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022.
Araujo D, Greystoke A, Bates S, Bayle A, Calvo E, Castelo-Branco L, de Bono J, Drilon A, Garralda E, Ivy P, Kholmanskikh O, Melero I, Pentheroudakis G, Petrie J, Plummer R, Ponce S, Postel-Vinay S, Siu L, Spreafico A, Stathis A, Steeghs N, Yap C, Yap TA, Ratain M, Seymour L. Araujo D, et al. Among authors: melero i. Ann Oncol. 2023 Jan;34(1):48-60. doi: 10.1016/j.annonc.2022.09.158. Epub 2022 Sep 29. Ann Oncol. 2023. PMID: 36182023 Free article. Review.
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial.
Ascierto PA, Mandalà M, Ferrucci PF, Guidoboni M, Rutkowski P, Ferraresi V, Arance A, Guida M, Maiello E, Gogas H, Richtig E, Fierro MT, Lebbè C, Helgadottir H, Queirolo P, Spagnolo F, Tucci M, Del Vecchio M, Gonzales Cao M, Minisini AM, De Placido S, Sanmamed MF, Mallardo D, Curvietto M, Melero I, Palmieri G, Grimaldi AM, Giannarelli D, Dummer R, Chiarion Sileni V. Ascierto PA, et al. Among authors: melero i. J Clin Oncol. 2023 Jan 10;41(2):212-221. doi: 10.1200/JCO.21.02961. Epub 2022 Sep 1. J Clin Oncol. 2023. PMID: 36049147 Clinical Trial.
352 results